BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1100 related articles for article (PubMed ID: 12384546)

  • 1. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.
    Cohen CJ; Hoffmann N; Farago M; Hoogenboom HR; Eisenbach L; Reiter Y
    Cancer Res; 2002 Oct; 62(20):5835-44. PubMed ID: 12384546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isolation and characterization of human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells directed toward the widely expressed tumor T-cell epitopes of the telomerase catalytic subunit.
    Lev A; Denkberg G; Cohen CJ; Tzukerman M; Skorecki KL; Chames P; Hoogenboom HR; Reiter Y
    Cancer Res; 2002 Jun; 62(11):3184-94. PubMed ID: 12036932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.
    Cohen CJ; Denkberg G; Lev A; Epel M; Reiter Y
    J Mol Recognit; 2003; 16(5):324-32. PubMed ID: 14523945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant antibodies with T-cell receptor-like specificity: novel tools to study MHC class I presentation.
    Denkberg G; Reiter Y
    Autoimmun Rev; 2006 Apr; 5(4):252-7. PubMed ID: 16697965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies.
    Cohen CJ; Sarig O; Yamano Y; Tomaru U; Jacobson S; Reiter Y
    J Immunol; 2003 Apr; 170(8):4349-61. PubMed ID: 12682272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fab antibodies capable of blocking T cells by competitive binding have the identical specificity but a higher affinity to the MHC-peptide-complex than the T cell receptor.
    Neumann F; Sturm C; Hülsmeyer M; Dauth N; Guillaume P; Luescher IF; Pfreundschuh M; Held G
    Immunol Lett; 2009 Aug; 125(2):86-92. PubMed ID: 19524620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of human antibody fragments directed against tumor T-cell epitopes for adoptive T-cell therapy.
    Willemsen R; Chames P; Schooten E; Gratama JW; Debets R
    Cytometry A; 2008 Nov; 73(11):1093-9. PubMed ID: 18785268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct visualization of distinct T cell epitopes derived from a melanoma tumor-associated antigen by using human recombinant antibodies with MHC- restricted T cell receptor-like specificity.
    Denkberg G; Cohen CJ; Lev A; Chames P; Hoogenboom HR; Reiter Y
    Proc Natl Acad Sci U S A; 2002 Jul; 99(14):9421-6. PubMed ID: 12093904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T cells recognize PD(N/T)R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1.
    Pisarev VM; Kinarsky L; Caffrey T; Hanisch FG; Sanderson S; Hollingsworth MA; Sherman S
    Int Immunopharmacol; 2005 Feb; 5(2):315-30. PubMed ID: 15652762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T-cell receptor-like antibodies: novel reagents for clinical cancer immunology and immunotherapy.
    Noy R; Eppel M; Haus-Cohen M; Klechevsky E; Mekler O; Michaeli Y; Denkberg G; Reiter Y
    Expert Rev Anticancer Ther; 2005 Jun; 5(3):523-36. PubMed ID: 16250828
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [MHC tetramers: tracking specific immunity].
    Kosor E; Gagro A; Drazenović V; Kuzman I; Jeren T; Rakusić S; Rabatić S; Markotić A; Gotovac K; Sabioncello A; Cecuk E; Kerhin-Brkljacić V; Gjenero-Margan I; Kaić B; Mlinarić-Galinović G; Kastelan A; Dekaris D
    Acta Med Croatica; 2003; 57(4):255-9. PubMed ID: 14639858
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing vaccine potency using TCRmimic antibodies.
    Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
    Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes.
    Ogg GS; Dunbar PR; Cerundolo V; McMichael AJ; Lemoine NR; Savage P
    Br J Cancer; 2000 Mar; 82(5):1058-62. PubMed ID: 10737389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells.
    Jerome KR; Barnd DL; Bendt KM; Boyer CM; Taylor-Papadimitriou J; McKenzie IF; Bast RC; Finn OJ
    Cancer Res; 1991 Jun; 51(11):2908-16. PubMed ID: 1709586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequencies of tetramer+ T cells specific for the wild-type sequence p53(264-272) peptide in the circulation of patients with head and neck cancer.
    Hoffmann TK; Donnenberg AD; Finkelstein SD; Donnenberg VS; Friebe-Hoffmann U; Myers EN; Appella E; DeLeo AB; Whiteside TL
    Cancer Res; 2002 Jun; 62(12):3521-9. PubMed ID: 12067999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of bispecific heteroconjugated antibodies (anti-T cell antigen receptor x anti-MHC class II) to study activation of T cells with a full length or truncated antigen receptor zeta-chain.
    Wu S; Yang Y; Sadegh-Nasseri S; Ashwell JD
    J Immunol; 1993 Mar; 150(6):2211-21. PubMed ID: 8450208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of a human agonist cytotoxic T-lymphocyte epitope of human prostate-specific antigen.
    Terasawa H; Tsang KY; Gulley J; Arlen P; Schlom J
    Clin Cancer Res; 2002 Jan; 8(1):41-53. PubMed ID: 11801539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes.
    Brossart P; Schneider A; Dill P; Schammann T; Grünebach F; Wirths S; Kanz L; Bühring HJ; Brugger W
    Cancer Res; 2001 Sep; 61(18):6846-50. PubMed ID: 11559560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
    Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
    Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
    Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
    J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 55.